Johnson & Johnson (NYSE:JNJ): Catalysts for the Stock

It’s been a positive year for Johnson & Johnson (NYSE:JNJ). The stock is up over 15% since the start of the year. Johnson & Johnson (NYSE:JNJ)’s pipeline is pretty strong, and analysts think the stock will gain even more in the coming months. Johnson & Johnson is set to launch at least 10 new drugs by the end of 2021. Last year, the company spent about $9 billion on research and development in order to find new revenue streams and technologies.

Johnson & Johnson ’s leukemia drug Imbruvica has been a blockbuster. In the first quarter, Imbruvica’s sales jumped by 57% as compared to the same period last year. Analysts are also bullish on the stock after the company’s $30 billion acquisition of Swiss medical company Actelion .

Based on the analysts' estimates both the revenue and the net result would be the highest in years. For this year Johnson & Johnson 's revenue will be around 75,66 billion Dollar. This is according to the average of the analysts' estimates. The expected revenue would be the highest in her history. This is slightly more than 2016's revenue of 71,89 billion Dollar.

Historical revenues and results Johnson & Johnson plus estimates 2017

financial analysis

The analysts anticipate for 2017 a record net profit a 19,55 billion Dollar. For this year the consensus of Johnson & Johnson 's result per share is a profit of 7,1 Dollar. The price/earnings-ratio therefor is 18,72.

Per share the analysts expect a dividend of 3,34 Dollar per share. The dividend yield is then 2,51 percent. The average dividend yield of the health care companies equals a limited 0,12 percent.

Most recent target prices around 136 Dollar

The most recent recommendations for the health care company are from Morgan Stanley , JP Morgan and Jefferies & Co..

Based on the current number of shares Johnson & Johnson 's market capitalization equals 366,16 billion Dollar.

Monday the stock closed at 132,9 Dollar.

Historical stock prices Johnson & Johnson

financial analysis johnson&johnson

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.